Metabolites of the ring-substituted stimulants MDMA,methylone and MDPV differentially affect human monoaminergic systems

Abstract

Background:

Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethcathinone (methylone) and 3,4-methylenedioxypyrovalerone (MDPV) can interact with monoaminergic systems.

Aim:

Interactions of metabolites of MDMA, methylone and MDPV with human monoaminergic systems were assessed.

Methods:

The ability of parent drugs and their metabolites to inhibit uptake of tritiated norepinephrine, dopamine and serotonin (5-HT) was assessed in human embryonic kidney 293 cells transfected with human monoamine transporters. Binding affinities and functional activity at monoamine transporters and various receptor subtypes were also determined.

Results:

MDMA and methylone displayed greater potency to inhibit norepinephrine uptake as compared to their effects on dopamine and 5-HT uptake. N-demethylation of MDMA failed to alter uptake inhibition profiles, whereas N-demethylation of methylone decreased overall transporter inhibition potencies. O-demethylenation of MDMA, methylone and MDPV resulted in catechol metabolites that maintained norepinephrine and dopamine uptake inhibition potencies, but markedly reduced activity at 5-HT uptake. O-methylation of the catechol metabolites significantly decreased norepinephrine uptake inhibition, resulting in metabolites lacking significant stimulant properties.

Conclusions:

Several metabolites of MDMA, methylone and MDPV interact with human transporters and receptors at pharmacologically relevant concentrations. In particular, N-demethylated metabolites of MDMA and methylone circulate in unconjugated form and could contribute to the in vivo activity of the parent compounds in human users.

Keywords

MDMA methylone MDPV metabolite transporter

Get full access to this article

View all access options for this article.

References

Anizan

Concheiro

Lehner

et al . (2016) Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: Relationship to pharmacodynamic effects. Addict Biol 21: 339–347.

Anizan

Ellefsen

Concheiro

et al . (2014) 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. Anal Chim Acta 827: 54–63.

Antolino-Lobo

Meulenbelt

Molendijk

et al . (2011) Induction of glutathione synthesis and conjugation by 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dihydroxymethamphetamine (HHMA) in human and rat liver cells, including the protective role of some antioxidants. Toxicology 289: 175–184.

Baumann

Ayestas

Jr. Partilla

et al . (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192–1203.

Baumann

Bukhari

Lehner

et al . (2017) Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Curr Top Behav Neurosci 32: 93–117.

Baumann

Partilla

Lehner

et al . (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38: 552–562.

Baumann

Zolkowska

Kim

et al . (2009) Effects of dose and route of administration on pharmacokinetics of (+ or −)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37: 2163–2170.

Carmo

Brulport

Hermes

et al . (2006) Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘ecstasy’) cytotoxicity. Pharmacogenet Genomics 16: 789–799.

Concheiro

Baumann

Scheidweiler

et al . (2014) Nonlinear pharmacokinetics of (+/−)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos 42: 119–125.

10.

de la Torre

Farre

Roset

et al . (2004) Human pharmacology of MDMA. Ther Drug Monit 26: 137–144.

11.

de la Torre

Yubero-Lahoz

Pardo-Lozano

et al . (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinicallyrelevant? Front Genet 3: 235.

12.

Del Bello

Sakloth

Partilla

et al . (2015) Ethylenedioxy homologs of N-methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine. Bioorg Med Chem 23: 5574–5579.

13.

Ellefsen

Concheiro

Suzuki

et al . (2015) Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. Forensic Toxicol 33: 202–212.

14.

Elmore

Dillon-Carter

Partilla

et al . (2017) Pharmacokinetic profiles and pharmacodynamic effects for methylone and its metabolites in rats. Neuropsychopharmacology 42: 649–660.

15.

Escobedo

O’Shea

Orio

et al . (2005) A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol 144: 231–241.

16.

Escubedo

Abad

Torres

et al . (2011) Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Neurochem Int 58: 92–101.

17.

Eshleman

Wolfrum

Hatfield

et al . (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85: 1803–1815.

18.

Fallon

Shah

Kicman

et al . (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965: 399–409.

19.

Forsling

Fallon

Shah

et al . (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135: 649–656.

20.

Henry

Allen

Shetty

et al . (2018) Elucidation of self-mediated enhancement of dopamine transport by the dopamine transporter which can be modulated by extracellular gate and N-terminal residues. Poster 680.6, Experimental Biology 2018, San Diego, 21–25 April 2018. Abstract: FASEB J, 32: 1.

21.

Kamata

Shima

Zaitsu

et al . (2006) Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36: 709–723.

22.

Kreth

Kovar

Schwab

et al . (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs. Biochem Pharmacol 59: 1563–1571.

23.

Liechti

(2015) Novel psychoactive substances (designer drugs): Overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 145: w14043.

24.

Lopez-Arnau

Martinez-Clemente

Carbo

et al . (2013) An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”. Prog Neuropsychopharmacol Biol Psychiatry 45: 64–72.

25.

Luethi

Kaeser

Brandt

et al . (2018a) Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology 134: 133–140.

26.

Luethi

Kolaczynska

Docci

et al . (2018b) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 134: 4–12.

27.

Luethi

Liechti

(2018) Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int J Neuropsychopharmacol 21: 926–931.

28.

Luethi

Trachsel

Hoener

et al . (2018c) Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology 134: 141–148.

29.

Mayer

Wimmer

Dillon-Carter

et al . (2016) Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol 173: 2657–2668.

30.

Meltzer

Butler

Deschamps

et al . (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem 49: 1420–1432.

31.

Meyer

Schuster

et al . (2010) Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 45: 1426–1442.

32.

Meyer

Peters

Maurer

(2008) The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos 36: 2345–2354.

33.

Miksys

Tyndale

(2002) Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27: 406–415.

34.

Moratalla

Khairnar

Simola

et al . (2017) Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog Neurobiol 155: 149–170.

35.

Mueller

Yuan

Felim

et al . (2009) Further studies on the role of metabolites in (+/−)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 37: 2079–2086.

36.

Pedersen

Petersen

Linnet

(2013) In vitro metabolism and pharmacokinetic studies on methylone. Drug Metab Dispos 41: 1247–1255.

37.

Rickli

Hoener

Liechti

. (2015a) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25: 365–376.

38.

Rickli

Kopf

Hoener

et al . (2015b) Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol 172: 3412–3425.

39.

Sandtner

Stockner

Hasenhuetl

et al . (2016) Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol Pharmacol 89: 165–175.

40.

Schindler

Thorndike

Blough

et al . (2014) Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol 171: 83–91.

41.

Schindler

Thorndike

Suzuki

et al . (2016) Pharmacological mechanisms underlying the cardiovascular effects of the “bath salt” constituent 3,4-methylenedioxypyrovalerone (MDPV). Br J Pharmacol 173: 3492–3501.

42.

Schmid

Vizeli

Hysek

et al . (2016) CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. Pharmacogenet Genomics 26: 397–401.

43.

Segura

Farre

Pichini

et al . (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: Use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44: 649–660.

44.

Segura

Ortuno

Farre

et al . (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14: 1203–1208.

45.

Simmler

Buser

Donzelli

et al . (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458–470.

46.

Stefkova

Zidkova

Horsley

et al . (2017) Pharmacokinetic, ambulatory, and hyperthermic effects of 3,4-methylenedioxy-N-methylcathinone (methylone) in rats. Front Psychiatry 8: 232.

47.

Steuer

Schmidhauser

Schmid

et al . (2015) Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine and its phase I and II metabolites following controlled administration to humans. Drug Metab Dispos 43: 1864–1871.

48.

Strano-Rossi

Cadwallader

de la Torre

et al . (2010) Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24: 2706–2714.

49.

Vizeli

Schmid

Prestin

et al . (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharmacol 27: 232–238.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.34 MB

0.04 MB